The clinical promise of Factor XI inhibition has given rise to a number of investigational compounds. Within this emerging class of Factor XI inhibitors, abelacimab – a highly selective, fully human monoclonal antibody – stands out due to its novel dual activity against both Factor XI and its activated form, Factor XIa. This dual activity enables profound suppression of Factor XI activity.
Abelacimab is a highly selective, fully human monoclonal antibody
PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
The groundbreaking results of our Phase 2 efficacy study – in which abelacimab significantly outperformed standard of care enoxaparin – was published in 2021 in the The New England Journal of Medicine.2
In this prospective study of 412 patients undergoing elective total knee arthroplasty, a single post-operative IV dose of abelacimab (75mg or 150mg) reduced the rate of venous thromboembolism by ~80% compared to standard of care enoxaparin (40mg SC once daily).
The ability of abelacimab to provide effective anticoagulation with a reduced rate of bleeding relative to DOACs will be assessed in the ongoing AZALEA-TIMI 71- TIMI STUDY GROUP study in atrial fibrillation.
Created for the heterogeneous real world, abelacimab has the promise of suitability for a broad spectrum of patients, no requirement for dosage adjustment in cases of renal or hepatic impairment and no interactions with other drugs.
It is planned to be available as a rapid-onset intravenous presentation to prevent VTEs in the inpatient setting and a once-monthly subcutaneous version for ongoing protection in the community, with the anticipation of improved adherence.
1 papagrigoriou, E. et al nat Struct Mol Biol 2006; 13:557-558
2 Verhamme P et al. n Engl J Med 2021; 385:609-617
